<DOC>
<DOCNO>EP-0623216</DOCNO> 
<TEXT>
<INVENTION-TITLE>
IMMUNOCHEMICAL DETECTION OF $i(IN VIVO) ADVANCED GLYCOSYLATION ENDPRODUCTS
</INVENTION-TITLE>
<CLASSIFICATIONS>C07K1618	C07K1600	C07K1900	G01N3368	C07K1107	C07K1644	G01N3372	G01N3372	A61K39395	C07K1644	G01N3353	C07K1900	C07K1476	C07K122	G01N3353	C07K1600	C07K14435	G01N3368	A61K3800	C07K100	C07K1618	A61K39395	A61K3800	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>C07K	C07K	C07K	G01N	C07K	C07K	G01N	G01N	A61K	C07K	G01N	C07K	C07K	C07K	G01N	C07K	C07K	G01N	A61K	C07K	C07K	A61K	A61K	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>C07K16	C07K16	C07K19	G01N33	C07K1	C07K16	G01N33	G01N33	A61K39	C07K16	G01N33	C07K19	C07K14	C07K1	G01N33	C07K16	C07K14	G01N33	A61K38	C07K1	C07K16	A61K39	A61K38	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
The circulating advanced glycosylation endproducts Hb-AGE, serum AGE-peptides and urinary AGE-peptides are disclosed as long term markers of diseases and dysfunctions having as a characteristic the presence of a measurable difference in AGE concentration. Diagnostic and therapeutic protocols taking advantage of the characteristics of these AGEs are disclosed. Antibodies which recognize and bind to in vivo-derived advanced glycosylation endproducts are also disclosed. Methods of using these antibodies as well as pharmaceutical compositions are also disclosed, along with numerous diagnostic applications, including methods for the measurement of the presence and amount of advanced glycosylation endproducts in both plants and animals, including humans, as well as in cultivated and synthesized protein material for therapeutic use.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
UNIV ROCKEFELLER
</APPLICANT-NAME>
<APPLICANT-NAME>
THE ROCKEFELLER UNIVERSITY
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
BUCALA RICHARD J
</INVENTOR-NAME>
<INVENTOR-NAME>
BUCALA, RICHARD, J.
</INVENTOR-NAME>
</INVENTORS>
<DESCRIPTION>
The following articles are noted as they are generally
directed to the subject matter of the present invention:
"FUNCTION OF MACROPHAGE RECEPTOR FOR NONENZYMATICALLY
GLYCOSYLATED PROTEINS IS MODULATED BY INSULIN LEVELS",
Vlassara, Brownlee and Cerami, DIABETES (1986), Vol. 35
Supp. 1, Page 13a; "ACCUMULATION OF DIABETIC RAT
PERIPHERAL NERVE MYELIN BY MACROPHAGES INCREASES WITH THE
PRESENCE OF ADVANCED GLYCOSYLATION ENDPRODUCTS",
Vlassara, H., Brownlee, M., and Cerami, A. J. EXP. MED.
(1984), Vol. 160, pp. 197-207; "RECOGNITION AND UPTAKE OF
HUMAN DIABETIC PERIPHERAL NERVE MYELIN By MACROPHAGES",
Vlassara, H., Brownlee, M., and Cerami, A. DIABETES
(1985), Vol. 34, No. 6, pp. 553-557; "HIGH-AFFINITY-RECEPTOR-MEDIATED
UPTAKE AND DEGRADATION OF GLUCOSE-MODIFIED
PROTEINS: A POTENTIAL MECHANISM FOR THE REMOVAL
OF SENESCENT MACROMOLECULES", Vlassara H., Brownlee, M.,
and Cerami, A., PROC. NATL. ACAD. SCI. U.S.A. (Sept.
1985), Vol. 82, pp. 5588-5592; "NOVEL MACROPHAGE RECEPTOR
FOR GLUCOSE-MODIFIED PROTEINS IS DISTINCT FROM PREVIOUSLY
DESCRIBED SCAVENGER RECEPTORS", Vlassara, H., Brownlee,
M., and Cerami, A. JOUR. EXP. MED. (1986), Vol. 164, pp.
1301-1309; "ROLE OF NONENZYMATIC GLYCOSYLATION IN
ATHEROGENESIS", Cerami, A., Vlassara, H., and Brownlee,
M., JOURNAL OF CELLULAR BIOCHEMISTRY (1986), Vol. 30, pp.
111-120; "CHARACTERIZATION OF A SOLUBILIZED CELL SURFACE
BINDING PROTEIN ON MACROPHAGES SPECIFIC FOR PROTEINS
MODIFIED NONENZYMATICALLY BY ADVANCED GLYCOSYLATION END
PRODUCTS", Radoff, S., Vlassara, H. and Cerami, A., ARCH.
BIOCHEM. BIOPHYS. (1988), Vol. 263, No. 2, pp. 418-423;
"ISOLATION OF A SURFACE BINDING PROTEIN SPECIFIC FOR
ADVANCED GLYCOSYLATION ENOPRODUCTS FROM THE MURINE
MACROPHAGE-DERIVED CELL LINE RAW 264.7", Radoff, S.,
Vlassara, H., and Cerami, A., DIABETES, (1990), Vol. 39, 
pp. 1510-1518; "TWO NOVEL RAT LIVER MEMBRANE PROTEINS
THAT BIND ADVANCED GLYCOSYLATION ENDPRODUCTS:
RELATIONSHIP TO MACROPHAGE RECEPTOR FOR GLUCOSE-MODIFIED
PROTEINS", Yang, Z., Makita, Z., Horii, Y., Brunelle, S.,
Cerami, A., Sehajpal, P., Suthanthiran, M. and Vlassara,
H., J. EXP. MED., Vol. 174, pp. 515-524; "HUMAN AND RAT
MESANGIAL CELL RECEPTORS FOR GLUCOSE-MODIFIED PROTEINS:
POTENTIAL ROLE IN KIDNEY TISSUE REMODELLING AND DIABETIC
NEPHROPATHY", Skolnik, E., Yang, Z., Makita, Z., Radoff,
S., Kirstein, M., and Vlassara, H., J. EXP. MED., Vol.
174, pp. 931-939; and "HEMOGLOBIN-AGE: A CIRCULATING
MARKER OF ADVANCED GLYCOSYLATION", Makita, Z., Vlassara,
H., Rayfield, E., Cartwright, K., Friedman, E., Rodby,
R., Cerami, A.,
</DESCRIPTION>
<CLAIMS>
An antibody to 
in vivo
-produced advanced glycosylation end-products (AGEs)
obtainable by immunisation of a mammal with AGE-RNAse, wherein said antibody is

an anti-AGE antibody having the characteristics tat it is cross-reactive with advanced
glycosylation end-products formed 
in vitro
, reacts with an immunological epitope
common to AGEs, but which does not react wit the following model AGEs:


2-(2-furoyl)-4(5)-(2-furanyl)-1H-imidazole (FFI), 1-alkyl-2-formyl-3,4-diglycosyl
pyrrole (AFGP), 5-hydroxymethyl-1-alkylpyrrole-2-carbaldehyde (pyrraline),

carboxymethyllysine and pentosidine,

wherein reactivity is detected in a competitive solid phase assay format, wherein bovine
serum albumin (BSA)-AGE obtained by incubation of BSA with glucose is absorbed to

said solid phase and said model AGE is tested as the inhibitor of binding said antibody
to said BSA-AGE.
An anti-AGE antibody according to claim 1, wherein said anti-AGE antibody is
reactive with 
in vivo
-produced advanced glycosylation end-products selected from the
group consisting of Hb-AGE, AGE-HSA, serum AGE-peptides, urinary AGE-peptides

and combinations thereof.
An antiserum containing an anti-AGE antibody according to any preceding
claim.
An antiserum containing an anti-AGE antibody according to any of claims 1-3
that is reactive with advanced glycosylation end-products formed 
in vivo
 selected from
the group consisting of AGE-RNAse, AGE haemoglobin, AGE-albumen, AGE-LDL,

AGE collagen type IV, AGE-BSA reduced wit NaBH
4
, and mixtures of these
compounds.
The antiserum according to claim 4 wherein said antiserum is prepared by
immunising a mammal with a foreign protein or reaction product of a protein incubated

with a reducing sugar. 
The antiserum of claim 5 wherein said antiserum is
prepared by immunising a mammal with AGE-RNAse.
The antiserum of claim 3 wherein said antiserum reacts
with diabetic tissue and serum that contain elevated levels

of advanced glycosylation end-products.
The antiserum of claim 7 wherein said antiserum reacts
with rat aortic collagen from subjects with experimentally-induced

diabetes, and with human serum from diabetic
subjects.
The antiserum of claim 3 wherein said epitope is
formed by the incubation of a reducing sugar with a

proteinaceous material selected from the group consisting of
RNAse, haemoglobin, lysine, collagen type IV, LDL, BSA and

HSA.
The antiserum of claim 9 wherein the reducing sugar
is selected from the group consisting of glucose, glucose-6-phosphate,

fructose and ribose.
The antiserum of claim 3 wherein said epitope is
formed by the incubation of glucose with RNAse.
The antiserum of claim 3 wherein the 
in vito
-formed
advanced glycosylation end-products with which said

antiserum is reactive have formed and exhibit fluorescence.
The antiserum of claim 3 wherein the in vivo-formed
advanced glycosylation end-products with which said

antiserum is reactive are inhibited in their formation by
the presence of an inhibitor of advanced glycosylation

capable of reacting with an active carbonyl of an early
glycosylation product. 
An antiserum according to any one of claims 3 to 13
labelled with a detectable label.
An anti-AGE antibody to 
in vivo
 produced advanced
glycosylation end-products prepared from the antiserum of

any one of claims 3-13.
The antibody of claim 15 wherein said antiserum is
polyclonal and is raised in rabbits against bovine RNAse

incubated with glucose.
The antibody of any one of claims 1, 2, 15 or 16
labelled with a detectable label.
The antibody or antiserum of either of claims 14 or
17 wherein said label is selected from the group consisting

of enzymes, chemicals which fluoresce and radioactive
elements.
A pharmaceutical composition containing an anti-AGE
antibody according to any one of claims 1, 2, 15 or 16 in

combination with a pharmaceutically-acceptable carrier.
An anti-AGE antibody of any one of claims 1, 2, 15 or
16 or pharmaceutical composition according to claim 19 for

use in therapy.
A method for purifying a quantity of a protein
material prepared for use as a therapeutic agent to remove

any protein-AGEs present therein, said method comprising the
steps of:


a) contacting said quantity of protein material suspected
of containing said protein AGEs with an anti-AGE antibody

according to claim 1 for a period of time sufficient for
said protein-AGEs to bind to said anti-AGE antibody; and
b) separating said protein-AGEs bound to said anti-AGE 
antibody from the remainder of said protein material.
A method for detecting the presence of advanced
glycosylation end-products (AGEs) in a biological sample

comprising the steps of:

(a) contacting said biological sample 
in vitro
 with the
antibody of any one of claims 1, 2, 15, 16 or 18;
(b) allowing the formation of reaction complexes which
comprise said antibody and said AGEs; and
(c) detecting the formation of said reaction complexes in
said biological sample; wherein detection of said reaction

complexes indicates the presence of AGEs in said biological
sample.
The method of claim 22 wherein said anti-AGE antibody
is bound to a solid phase support.
The method of claim 23 further comprising contacting
said biological sample in step (a) with a labelled AGE which

can form a reaction complex with said anti-AGE antibody,
removing any substances not part of said reaction complex

formed in step (b) prior to step (c), wherein the formation
of reaction complexes comprising said anti-AGE antibody and

said AGEs in said biological sample is detected by observing
a decrease in the amount of said labelled AGE in reaction

complexes with said anti-AGE antibody when said sample is
compared to a control sample lacking AGEs.
The method of claim 23
wherein said detection step (c) comprises a sandwich assay. 
The method of claim 22 wherein said AGEs are bound to
a solid phase support and wherein said anti-AGE antibody is

labelled and forms a reaction complex with said AGEs,
further comprising contacting said biological sample in step

(a) with said AGEs and said labelled antibody, removing any
substance not part of said reaction complex prior to step

(c), wherein the formation of said reaction complexes
comprising said antibody and said AGEs in said sample is

detected by observing a decrease in the amount of labelled
antibody in said reaction complexes with said AGEs compared

to a control sample lacking AGEs.
The method according to claim 26 wherein said AGE is
BSA-AGE.
The method of claim any one of claims 22-27 wherein
said biological sample is selected from the group consisting

of blood; plasma; urine; cerebrospinal fluid; lymphatic
fluid; tissue; plant matter; edible animal matter; a product

of the reaction between protein and a sugar; a product of
the reaction between DNA and a sugar, and mixtures thereof.
The method of claim any one of claims 22-27 wherein
said AGE in said biological sample is selected from the

group consisting of HB-AGE, mammalian serum albumin-AGE,
serum AGE-proteins, serum AGE-peptides, urinary AGE-peptides,

and combinations thereof.
The method of claim 29 wherein said mammalian serum
albumin-AGE is human serum albumin-AGE.
A method of quantifying the formation of reaction 
complexes between AGEs and an anti-AGE antibody by measuring

the extent of binding detected in said biological sample
according to the method of any one of claims 22 to 30

wherein the quantity of said reaction complexes corresponds
to the level of AGEs in said biological sample.
A method for monitoring the course of a disease or for
monitoring therapeutic treatment of a disease associated

with elevated AGE levels in a mammalian subject comprising
determining the level of AGEs in a series of biological

samples obtained at different time points from a mammalian
subject by the method of any one of claims 22 to 30.
The method of claim 31 wherein said AGE being measured
is selected from the group consisting of HB-AGE, AGE-HSA,

serum AGE-proteins, serum AGE-peptides, and urinary AGE-peptides.
The method according to claims 22 to 30 wherein at
least a portion of the AGEs are derived from fructose.
An 
in vitro
 method for the long term monitoring of
blood sugar in a mammal comprising the following steps:


a) obtaining a sample of serum protein from a mammal;
b) determining the level of advanced glycosylation of
said serum protein according to the method of any one of

claims 22 to 30; and
c) comparing the level of advanced glycosylated serum
protein to a level in said mammal obtained at an earlier

time, wherein an increase indicates an increase in blood
sugar, and a decrease indicates a decrease in blood sugar.
An 
in vitro
 method for monitoring time-integrated
blood sugar levels comprising determining the level of AGEs

in a biological sample comprising quantifying the formation
of said reaction complexes by measuring the extent of

binding detected in said biological sample according to the
method of any one of claims 22 to 30 wherein the quantity of

said reaction complexes corresponds to the level of AGEs in
said biological sample.
A method for diagnosing the presence of a disease or
disorder associated with elevated AGE levels in a mammalian

subject comprising:

(a) determining the level of AGEs in a biological sample by
quantifying the formation of said reaction complexes by

measuring the extent of binding detected in said biological
sample according to the method of any one of claims 22 to

30; and
(b) comparing the level determined in step (a) to a level
of AGEs present in a normal mammalian subject of the same

species; wherein detection of a higher level of AGEs as
compared to a normal level is indicative of the presence of

a disease or disorder associated with elevated levels of
AGEs.
The method of claim 37 wherein the disease or disorder
is selected from the group consisting of diabetes,

glycaemia, urinary diseases and dysfunctions, chronological
aging, the effects of protein aging, and combinations

thereof.
A test kit for measuring the presence of AGEs in a
biological sample 
in vitro
, comprising:

(a) an anti-AGE antibody according to any one of claims 1,
2, 15, and 16; 
(b) a labelled reagent capable of forming a complex with an
AGE or with said anti-AGE antibody; and
(c) directions for use of said kit.
The test kit of claim 39 wherein said anti-AGE
antibody is bound to a solid phase.
The test kit of either of claims 39 or 40 wherein the
labelled reagent is a labelled anti-AGE antibody reactive

with 
in vivo
-produced AGE.
The test kit of claim 39 wherein said labelled reagent
is a labelled AGE.
The test kit of claim 39 wherein said labelled reagent
is said anti-AGE antibody, further comprising an isolated

AGE bound to a solid phase support.
The test kit according to claim 44 wherein the
isolated AGE is BSA-AGE.
The test kit of any one of claims 39 to 44 wherein
said labelled reagent is labelled with a label selected from

the group consisting of an enzyme, a chemical that
fluoresces, and a radioactive element.
</CLAIMS>
</TEXT>
</DOC>
